[go: up one dir, main page]

WO2002092114A1 - Agents prophylactiques et/ou remedes aux infections des poissons - Google Patents

Agents prophylactiques et/ou remedes aux infections des poissons Download PDF

Info

Publication number
WO2002092114A1
WO2002092114A1 PCT/JP2002/004457 JP0204457W WO02092114A1 WO 2002092114 A1 WO2002092114 A1 WO 2002092114A1 JP 0204457 W JP0204457 W JP 0204457W WO 02092114 A1 WO02092114 A1 WO 02092114A1
Authority
WO
WIPO (PCT)
Prior art keywords
fish
shellfish
fucoidan
feed
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/004457
Other languages
English (en)
Japanese (ja)
Inventor
Takeshi Yoshimoto
Hiroshi Omura
Takekazu Okumura
Masumi Nakao
Sadao Ueyama
Masato Nagaoka
Kazuaki Hamasato
Teturo Yamashita
Akio Kanemitsu
Toshiro Kawano
Manabu Sasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yakult Honsha Co Ltd
Miyako Kagaku Co Ltd
Original Assignee
Yakult Honsha Co Ltd
Miyako Kagaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Co Ltd, Miyako Kagaku Co Ltd filed Critical Yakult Honsha Co Ltd
Priority to JP2002589031A priority Critical patent/JP4294326B2/ja
Priority to KR10-2003-7014445A priority patent/KR20030094382A/ko
Publication of WO2002092114A1 publication Critical patent/WO2002092114A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a drug for preventing and / or treating infection of fish and shellfish with a virus or a pathogenic bacterium, a feed containing the same, and a method of cultivating fish and shellfish by administering the same.
  • mozuku containing a large amount of sulfated polysaccharides such as antibiotics and fucoidan was often expensive and difficult to produce for aquaculture feed.
  • an object of the present invention is to provide an inexpensive and highly safe agent for preventing and / or treating fish and shellfish, which has excellent preventive and therapeutic effects on viral infection and bacterial infection. Disclosure of the invention
  • the present invention relates to a fish and shellfish characterized by containing one or more components selected from the group consisting of algae of the genus Trolocombus, brown algae of the genus Bombyx, giant kelp, algae of the genus Ascophyllum, and extracts thereof. It provides a prophylactic and / or therapeutic agent for infection.
  • the present invention also provides a feed for culturing fish and shellfish, which contains the agent for preventing and / or treating infection.
  • the present invention provides a method for cultivating fish and shellfish, which comprises administering the preventive and / or therapeutic agent or the feed or the feed.
  • the present invention relates to an algae of the genus Trolocombus, And a method for preventing and / or treating fish and shellfish infectious diseases characterized by administering an effective amount of one or more components selected from the group consisting of brown algae of the genus Ascophyllum and extracts thereof. . BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 shows the effect of various seaweed extracts on PRDV infection.
  • FIG. 2 is a diagram showing the effects of various seaweed extracts on PRDV infection.
  • FIG. 3 is a graph showing the effect of using various seaweed extracts and fucoidan in combination.
  • FIG. 4 is a graph showing the effect of using various seaweed extracts in combination with fucoidan and Bacillus pamilus.
  • Trolocomb used in the present invention is a brown algae belonging to the genus Trolocomb that frequently breeds in the eastern part of Hokkaido, such as Kushiro and Nemuro, and has a thick, slender strip of about l to 5 m in length and about 10 cm in width. It has leaf-like leaves, and its surface has complex cloud-like irregularities.
  • Algae are known to contain nutrients such as potassium and sodium, vitamin A, chloride and alginic acid.
  • Trolocum Koreaniella crassifolia
  • Gagome Korean lmaniel la gyrata
  • any of them can be suitably used.
  • Kazime is a brown algae of the genus Ceratophyta that grows on the rocky shores of the Pacific coast south of Kanto.It has a plate-shaped or band-shaped central leaf at the top of its elongated stem, and its lateral lobes have wings spread to the left and right. Is recognized. Algae are rich in nutrients such as mannitol, eel, and alginic acid, and are also used as raw materials for their production.
  • the brown algae of the genus Ecklonia used in the present invention include, for example, Ecklonia maxima, Ecklonia kurome, and Ecklonia stoloni fera Etc., and any of them can be suitably used.
  • the giant kelp used in the present invention is a brown alga of the order Laminaria that grows in a rocky reef along the coast of Power Reformia in North America, and is known to grow to several tens of meters with a long and thin stem attached to many side leaves. I have. Algae contain calcium and vitamins
  • Ascophyllum algae is a brown alga of the genus Hibamata that frequently breeds along the northern European coast, and contains nutrients such as veins, auxins, cytokinins, abscisic acid, polysaccharides, oligosaccharides, minerals, vitamins, and amino acids. It is known as a seaweed with a high alginic acid content.
  • Ascophyllum algae used in the present invention include, for example, Ascophyllum nodosum.
  • the above-mentioned seaweeds may be used as they are, or those obtained by pulverization or the like, or those extracted with water, a hydrophilic solvent, or a mixture thereof.
  • the extraction temperature and time may be selected appropriately for each seaweed.
  • the extraction may be carried out at a low or room temperature for several days, or may be performed by heating and extracting for several minutes to several hours.
  • the extract thus obtained can be used as it is, or may be subjected to purification treatment or the like within a range that does not impair the effect.
  • the agent for preventing and / or treating Z or the infection of the present invention further contain fucoidan in addition to the seaweed or its extract.
  • Fucoidan is a sulfated polysaccharide consisting mainly of fucose and having a molecular weight of around hundreds of thousands, and is abundantly contained in the brown alga Mozuku, Mizuki, Macombu, Wakame, Kombu, Amijigusa, etc. and is harmless to the human body belongs to.
  • the fucoidan used in the present invention may be a product obtained by pulverizing brown algae containing fucoidan, or may be a product obtained by extraction and purification using an appropriate method. Is not particularly limited, but from the viewpoint of cost and the like, Mozuku or Okinawa Mozuku is preferable.
  • the extraction method is usually used The method is not particularly limited as long as it is a method, and examples thereof include acid extraction and hot water extraction.
  • the polymer extracted from seaweed may be used after being reduced in molecular weight or oligosaccharide by hydrolysis, for example, by treatment with a weak acid.
  • the agent for preventing or treating infection of the present invention further comprises a bacterium belonging to Bacillus pamilus or Bacillus lentus.
  • Bacteria belonging to Bacillus pamilus or Bacillus' lentus used in the present invention include, in particular, Bacillus pamilus A-1 strain (FERM BP-6280) and Bacillus lentus A-2 strain disclosed in W98Z045402. (FERM BP-6278), Bacillus lentus A-3 (FERM BP-6279), and Bacillus pamilus A-4 (FERM BP-6281). Is preferred.
  • the agent for preventing and / or treating Z or the infection of the present invention can be administered as it is, or may be used by mixing or blending it with feed materials usually used for culturing fish and shellfish.
  • the amount to be mixed or added to the feed may be determined as appropriate according to the fish and shellfish and the culture method, but for example, about 10 mg / kg to 500 nig / kg, more preferably about 50 mg / kg to 30 Omg / kg, particularly It is preferable to mix 100 mg / kg to 20 Omg / kg.
  • the feed amount of feed containing the preventive and / or Z- or therapeutic agent for infection of the present invention is preferably about 3% of the body weight of fish and shellfish a day.
  • the amount of fucoidan may be appropriately determined according to the type of fish and shellfish, etc., and is usually about 50 mg / kg to 100 mg / kg, particularly preferably 60 mg / kg to 80 mg / kg. .
  • the cells may be administered as they are grown in a normal growth medium, for example, dried broth, or the like.
  • the recovered cells may be administered by centrifugation, standing, and removing the supernatant.
  • the cells may be freeze-dried together with excipients such as starch and skim milk.
  • the cells after culturing were supported on a carrier. May be administered.
  • the carrier used here is not particularly limited, but zeolite, maltstone, activated carbon, igneous rock, coral stone, and the like are preferable in terms of the ability to retain cells, and zeolite is particularly preferable in terms of cost.
  • the seaweed, fucoidan, and Bacillus bacterium can be administered separately. That is, the seaweed as it is or the extract may be fed directly, and fucoidan may be separately administered as it is, or a seaweed or an extract dried product containing the same may be administered.
  • the cells recovered from the Bacillus bacterium bacterium may be separately administered as it is or by being supported on a carrier by a separation means such as centrifugation. These may be mixed or blended with the breeding raw materials usually used for cultivation of fish and shellfish.
  • the amount of the seaweed mixed or mixed in the feed varies depending on the fish and shellfish and the cultivation method, but the amount of the above seaweed is generally 10 mg to 50 mg / kg of seafood per day for prevention of infection.
  • the dose may be set so as to be administered in an amount of about 50 mg to 30 Omg, particularly 100 mg to 20 Omg.
  • the amount of fucoidan may be usually set to be about 50 mg to 100 mg, especially 60 mg to 80 mg per kg of seafood per day.
  • the amount of the bacterium belonging to the genus Bacillus may be appropriately determined according to the type of fish and shellfish, and is usually 1 ⁇ 10 5 to 1 ⁇ 10 9 cfu / g—feed, especially 1 ⁇ 10 6 to 1 ⁇ 10 6 cfu / g.
  • the feed amount of feed containing these is preferably about 3% of the body weight of fish and shellfish a day.
  • the fish and shellfishes to which the agent for preventing or treating infection of the present invention can be applied are not particularly limited, and include freshwater fish, eel, koi, rainbow trout, ayu, tilapia, crucian carp, etc., and saltwater fish, Puri, Thailand, coho salmon.
  • Invertebrates include kuruma shrimp, ⁇ shevi (black taiga), white shrimp, korejabi, kazami and the like.
  • infectious diseases include viral infectious diseases such as iridovirus, birnavirus, and PRDV, and bacterial infectious diseases such as vibrio, pseudomonas, streptococci, and nodular disease. During ⁇ However, the effect on PRDV is high and preferable.
  • Salted seaweed (trocombe, kajime, ascophyllum nodsam, giant kelp) was used. Each seaweed was homogenized, suspended in the same amount of water as its wet weight, and desalted. Further, the suspension was suspended in water at a rate of 1 liter per 1 kg of algal cells, heated at 100 ° C. for 2 hours, and then allowed to stand at room temperature for extraction. The alga bodies were filtered off with a gauze, and the filtrate was centrifuged (9,000 rpm, 60 minutes). The supernatant was further dried to obtain each seaweed extract as a powder.
  • the raw material used was salted Okinawa mozuku.
  • Okinawa mozuku was suspended in water in the same amount as its wet weight to remove salts, and then adjusted to pH 3 by adding an aqueous hydrochloric acid solution. This suspension was heated at 100 ° C. for 10 minutes to extract fucoidan.
  • insoluble components were removed at 7,000 G using a centrifugal separator, and batch hydrofiltration was repeated at pH 3 using an ultrafiltration membrane with a molecular weight cut-off of 6,000. The low molecular weight fraction having a molecular weight of 6,000 or less was removed.
  • sodium hydroxide was added to adjust the pH to a range of 5.5 to 6.0.
  • the concentrated solution containing fucoidan as a main component was dried by spraying to obtain a powder of a fucoidan fraction of 5 g per 1 kg of wet algal cells.
  • This powder is hereinafter referred to as “Fucoidan (F15)”.
  • test group 1 normal feed (manufactured by Evian Kyowa) was used.
  • test group 2 tumor-administered group
  • 6 Omg (XF-240) of trolocomb was added per day to 1 kg of prawns in a normal feed, and the mixture was molded.
  • test group 2 Korean administration group
  • the mixture was added and mixed at a dose of 6 Omg (XF-241) per day for 1 kg of prawns to form and used.
  • test group 3 In test group 3 (giant kelp-administered group), in addition to the normal feed, the mixture was added, mixed and molded so that giant kelp 6 Omg (XF-242) was administered per lkg of prawns per day.
  • test group 4 ascofilm administration group
  • 6% Oscofilm In test group 4 (ascofilm administration group), in addition to the normal feed, 6% Oscofilm (XF-243) was administered per 1 kg of prawns per day, mixed and molded.
  • test prawns, breeding methods, and test methods were the same as in Example 3.
  • test plots 1 to 4 used the same feed as in Example 3.
  • test group 5 combination administration of trolocomb and fucoidan
  • the usual diet should be such that 15 mg of fucoidan (F15) and 10 Omg of trolocomb (XF-240) per kg of shrimp per day were administered.
  • the mixture was added, molded and used.
  • test zone 6 combination administration of kajime and fucoidan
  • normal feed should be such that 15 mg of fucoidan (F15) and 10 omg of kajime (XF-241) per kg of shrimp per day were administered. , Mixed and molded.
  • Test plot 7 Test plot 7
  • test area 8 (ascofilam and fucoidan combined administration area), 15 mg (F15) of fucoidan and 10 Omg (XF-243) of fucoidan / kg of shrimp per day were administered to normal feed. , And then molded and used.
  • test prawns, breeding methods, and test methods were the same as in Example 3.
  • feed For the control, normal feed (manufactured by Evian Kyowa) was used. In addition to the normal diet to test group 1 (Ba Chirusu group administered), feed 1 g per Bacillus' Parumisu A- 10 6 cells per share (Bacillus) added were mixed and used in molding.
  • Test group 2 (Tororo kelp, Fukoidan, Bacillus administered in combination District) to the normal feed in, the bus Chirusu-Pamirusu A- 1 share per feed lg 10 6 cells (hereinafter to as "Bacillus Pamirusu (B)", and Test mixture 3 (Kajime, Fucoidan and Bacillus combined) was added and mixed to give 15 mg of fucoidan (F15) and 1 mg of trolocomb (XF-240) per kg of prawns per day.
  • the administration group consisted of 10 6 Bacillus pamilus per g feed (B), 15 mg fucoidan per lkg of prawns per day (F15), and 1 K Omg (KF) per 1 g of feed.
  • test group 4 giant gelp and fucoidan bacillus combined administration group
  • 10 6 Bacillus' palmis per gram of feed (B), and Kle per day 15 mg of fucoidan (F15) and 1 giant kelp were added and mixed to give 1 O Omg (XF-242) per 1 kg of shrimp, and the mixture was used for shaping
  • Test group 5 (Ascofiram combined with fucoidan bacillus) ) Contains 10 6 Bacillus' palmis per gram of feed (B) and 15 mg of fucoidan per kg of shrimp per day (F15) and ascophyllum per gram of feed. The mixture was added and mixed to give a dose of 10 Omg (XF-243), molded and used.
  • PRDV mortality resulted from the combined use of 15 mg / kg fucoidan, a daily dose that would normally be ineffective, with Bacillus' palmis and trolocomb, cajime, ascofilam or giant kelp. It was confirmed that the inhibitory effect was more significantly enhanced.
  • the control group, the fucoidan-administered group, and the sample-administered group each received 80,000 white shrimp.
  • the amount of feed was increased as white shrimp grew, and the total feed rate was 2-20% per shrimp body weight.
  • the feeding rate of fucoidan-added feed and fucoidan / ascophyllum-added feed was set at 2% per body weight of shrimp, and normal feed was given if the total feeding rate was insufficient.
  • test group 1 normal feed (manufactured by NASA) was used.
  • test group 1 fucoidan-administered group
  • fucoidan was mixed with fucoidan at a dose of 60 mg / kg (F15) per 1 kg of white shrimp per day, and the mixture was molded and used to give a 2% feed.
  • Insufficient portions were fed with normal feed.
  • test plot 2 feeding plot
  • normal feed was fucoidan 15 mg / kg / kg of white shrimp per day.
  • Test method Each feed was fed continuously for 89 days. Depletion due to natural infection of PRDV was observed. White shrimp that died during the test period used the PCR method And attempted to detect the virus, and confirmed that the virus was the leading cause of death.
  • Table 1 shows the survival rates at the end of the breeding test.
  • the preventive and / or therapeutic agent of the present invention infection with fish and shellfish viruses and bacteria, particularly PRDV infection, can be effectively prevented and / or treated.
  • the prophylactic and / or therapeutic agent or Z may be used in a feed for the cultivation of fish and shellfish.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Animal Husbandry (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Fodder In General (AREA)
  • Birds (AREA)
  • Insects & Arthropods (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Feed For Specific Animals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'invention porte sur des agents prophylactiques et/ou sur des remèdes aux infections des poissons qui se caractérisent en ce qu'ils contiennent une algue appartenant au genre Kjellmaniella et Ecklonia, une algue géante et une autre algue appartenant au genre Ascophyllum ou des extraits de ceux-ci. Il est possible de prévenir et traiter de manière efficace les poissons infectés par des virus ou bactéries, notamment infectés par PRDV, au moyen des agents prophylactiques et/ou remèdes précités. Ces agents prophylactiques et/ou remèdes peuvent également être ajoutés à la nourriture dans les élevages de poissons.
PCT/JP2002/004457 2001-05-11 2002-05-08 Agents prophylactiques et/ou remedes aux infections des poissons Ceased WO2002092114A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2002589031A JP4294326B2 (ja) 2001-05-11 2002-05-08 魚介類の感染予防及び／又は治療剤
KR10-2003-7014445A KR20030094382A (ko) 2001-05-11 2002-05-08 어개류의 감염 예방 및/또는 치료제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-141272 2001-05-11
JP2001141272 2001-05-11

Publications (1)

Publication Number Publication Date
WO2002092114A1 true WO2002092114A1 (fr) 2002-11-21

Family

ID=18987754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/004457 Ceased WO2002092114A1 (fr) 2001-05-11 2002-05-08 Agents prophylactiques et/ou remedes aux infections des poissons

Country Status (4)

Country Link
JP (1) JP4294326B2 (fr)
KR (1) KR20030094382A (fr)
CN (1) CN1523995A (fr)
WO (1) WO2002092114A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004307346A (ja) * 2003-04-02 2004-11-04 Yakult Honsha Co Ltd 魚類の感染予防・治療剤
JP2015537022A (ja) * 2012-11-16 2015-12-24 ユニベルシテ ブレーズ パスカル−クレルモン ドゥジエム 硫酸化多糖組成物
CN107751051A (zh) * 2017-10-31 2018-03-06 合肥申仁养殖有限公司 一种降低鲫鱼发病率的养殖方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295956A2 (fr) * 1987-06-18 1988-12-21 Kureha Kagaku Kogyo Kabushiki Kaisha Utilisation d'un polysaccharide lié a une protéine pour préparer un médicament destiné au traitement du SIDA.
JPH06234652A (ja) * 1992-06-08 1994-08-23 Mitsubishi Petrochem Co Ltd 魚類の感染症予防用薬剤
JPH06234651A (ja) * 1992-06-08 1994-08-23 Mitsubishi Petrochem Co Ltd 魚類の感染症の予防用薬剤
JPH11180813A (ja) * 1997-12-19 1999-07-06 Ichimaru Pharcos Co Ltd 海藻抽出物含有抗菌・防腐剤
WO2000007586A1 (fr) * 1998-08-04 2000-02-17 Takara Shuzo Co., Ltd. Procede de culture et aliments
WO2000062785A1 (fr) * 1999-04-15 2000-10-26 Takara Shuzo Co., Ltd. Remedes
JP2000336035A (ja) * 1999-05-26 2000-12-05 Yakult Honsha Co Ltd 魚介類の感染症予防・治療剤

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295956A2 (fr) * 1987-06-18 1988-12-21 Kureha Kagaku Kogyo Kabushiki Kaisha Utilisation d'un polysaccharide lié a une protéine pour préparer un médicament destiné au traitement du SIDA.
JPH06234652A (ja) * 1992-06-08 1994-08-23 Mitsubishi Petrochem Co Ltd 魚類の感染症予防用薬剤
JPH06234651A (ja) * 1992-06-08 1994-08-23 Mitsubishi Petrochem Co Ltd 魚類の感染症の予防用薬剤
JPH11180813A (ja) * 1997-12-19 1999-07-06 Ichimaru Pharcos Co Ltd 海藻抽出物含有抗菌・防腐剤
WO2000007586A1 (fr) * 1998-08-04 2000-02-17 Takara Shuzo Co., Ltd. Procede de culture et aliments
WO2000062785A1 (fr) * 1999-04-15 2000-10-26 Takara Shuzo Co., Ltd. Remedes
JP2000336035A (ja) * 1999-05-26 2000-12-05 Yakult Honsha Co Ltd 魚介類の感染症予防・治療剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Anne BERESS et al., "A New Procedure for The Isolation of Anti-HIV Compounds (Polysaccharides and Polyphenols) from The Marine Alga Fucus Vesiculosus," J. Natural Products, 1993, Vol. 56, No. 4, pages 478 to 488 *
Ichiro YAMAMOTO, "Kaisorui no Men'eki Fukatsu Sayo (Kaiso no Kogan Sayo no Kenkyu kara)", Fragrance J. 1995, Vol. 5, pages 63 to 69 *
Takanari NAKANO et al., "Promoting Activity of Human IFN-Beta Production by Extracts of Marine Alagae from Japan," Umi to Daichi, 1996, Vol. 3, pages 65 to 71 *
Yoshihito OKADA, "Ko HIV Tennen Yakubutsu ni Kansuru Kenkyu", The Bulletin of The Meiji College of Pharmacy, 1994, No. 24, pages 26 to 30 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004307346A (ja) * 2003-04-02 2004-11-04 Yakult Honsha Co Ltd 魚類の感染予防・治療剤
JP2015537022A (ja) * 2012-11-16 2015-12-24 ユニベルシテ ブレーズ パスカル−クレルモン ドゥジエム 硫酸化多糖組成物
US9827277B2 (en) 2012-11-16 2017-11-28 Universite Blaise Pascal—Clermont II Sulphated polysaccharide composition
CN107751051A (zh) * 2017-10-31 2018-03-06 合肥申仁养殖有限公司 一种降低鲫鱼发病率的养殖方法

Also Published As

Publication number Publication date
CN1523995A (zh) 2004-08-25
KR20030094382A (ko) 2003-12-11
JP4294326B2 (ja) 2009-07-08
JPWO2002092114A1 (ja) 2004-08-26

Similar Documents

Publication Publication Date Title
Ringø et al. Application of vaccines and dietary supplements in aquaculture: possibilities and challenges
Montero-Rocha et al. Immunostimulation of white shrimp (Litopenaeus vannamei) following dietary administration of Ergosan
US20050020490A1 (en) A Method of Producing an Economical and Ecologically Sound Natural Immunobiotic Extract for Use as a Health Management Instrument and a Replacement for Growth Promotion Antibiotics in Livestock and Companion Animals.
El-Sayed et al. Effect of dietary chitosan on challenged Dicentrarchus labrax post larvae with Aeromonas hydrophila
KR20010071331A (ko) 갑각류 또는 어류용 사료첨가제 및 사료
JP4331824B2 (ja) 魚介類の感染症予防・治療剤
EP3737240A1 (fr) Bactéries probiotiques pour les poissons
JP2002012552A (ja) 動物・ヒト用免疫賦活調整剤及び動物・ヒトの感染症や皮膚病、癌の予防・治療方法
WO2002092114A1 (fr) Agents prophylactiques et/ou remedes aux infections des poissons
JP4398172B2 (ja) 魚類の感染予防・治療剤
CN1290429C (zh) 预防和治疗鱼类和有壳水生动物感染性疾病的药物
JP5553337B2 (ja) 海産魚白点病予防治療剤
CN103431191A (zh) 一种三疣梭子蟹成蟹用的免疫增强剂及其应用
EP4103213A1 (fr) Additif amélioré pour aliment aquacole
JP2002302454A (ja) アオサを原料とする抗ウイルス剤
CN105764520B (zh) 甲壳类的传染病的抑制方法
JPH1160495A (ja) 免疫系未成熟動物用の疾病予防剤
JPH06217712A (ja) 甲殻類用飼料
JPH10229831A (ja) 甲殻類の免疫賦活方法及び飼料添加剤
JP2016210689A (ja) 視神経保護剤
MARIN et al. CHITOSAN: A CRITICAL REVIEW OF CHITOSAN IMPACT IN AQUACULTURE
JP2008285431A (ja) 養殖魚のウイルス感染症の予防・治療組成物
KR20240046688A (ko) 수산양식에서의 규산
NO20171170A1 (en) Use of quillaja saponaria extracts for the prevention and control of viral infections in Fish.
JP3327974B2 (ja) 甲殻類用抗病性飼料

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CN EC ID JP KR PH

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002589031

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 028086678

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1020037014445

Country of ref document: KR